

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Rizzieri et al. Serial No.: 10/008,062 Filed: October 19, 2001

Confirmation No.: 5735 Group Art Unit: 1642 Examiner: Alana M. Harris

For:

ANTI-TENASCIN MONOCLONAL ANTIBODY THERAPY FOR LYMPHOMA

September 22, 2005

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Attached is a list of documents on form PTO-1449 together with a copy of each document. It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

This Information Disclosure is submitted in accordance with 37 C.F.R. § 1.97(b)(4), before the mailing of a first action after the filing of a Request for Continued Examination under 37 C.F.R. §1.114. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

Respectfully submitted,

Shawna Cannon Lemon Registration No. 53,888

Myers Bigel Sibley & Sajovec, P.A. P. O. Box 37428, Raleigh, NC 27627

Telephone: (919) 854-1400 Facsimile: (919) 854-1401 Customer No. 20792

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 674756836 US

Date of Deposit: September 22, 2005

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

Date of Signature: September 22, 2005

Substitute form 1449A/PTO	OE /	Complete if Known		
	AAR	Application Number	10/008,062	
INFORMATION DISCLOSURE	/	Filing Date	10/19/2001	
STATEMENT BY APPLICANT	2 8 8 7005	First Named Inventor	David Rizzieri	
017112111211112111111111111111111111111	SEP 2 18 LO	Group Art Unit	1642	
(use as many sheets as necessary)	10 20	Examiner Name	Alana M. Harris	
Sheet 1 of	1 TEN CHAPT	Attorney Docket Number	5405-252	

	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of Cited	
Initials*		Number	Kind Code (if known)	- Document	Document MM-DD-YYYY	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
		US-				
		US-				
•		US-				
		US-				
		US			•	
		US-				
		US-				
•		US-				
	·	US-				

				FOREIGN PA	ATENT DOCUMENTS		
	Cite		Foreign Patent Document		Name of Patentee or Applicant of Cited	Date of	Translation
Initials*	No.	Office	Number	Kind Code (if known)	- Document	Publication of Cited Document MM-DD-YYYY	
	1	wo	92/04464	A2	The Wistar Institute	03/19/1992	
		<u> </u>			<u> </u>		

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	2	Supplementary Partial European Search Report, EP 01 99 6085, 07/06/2005	
	3	Kaminski et al., "Radioimmunotherapy with iodine ¹³¹ I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience", <u>Blood</u> , 96(4):1259-1266 (2000)	
			<u> </u>

Examiner Signature	Date Considered	